Summary of Use during Lactation

Information in this record refers to the use of albumin, iodinated I 125 serum (I 125 HSA) as a diagnostic agent. The International Commission on Radiological Protection states that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 125 HSA. This usually will result in permanent discontinuation of breastfeeding for this infant.[1]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]

Drug Levels

I 125 is a low-energy pure gamma emitter with a physical half-life of 59.4 days.[1] Iodide is actively secreted into breastmilk and actively taken up by the mother's and infant's thyroid glands.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP. 2015;44(2) Suppl:319–21. [PubMed: 26069086]

2.

Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863–73. [PubMed: 10809203]

Substance Name

Albumin, Iodinated I 125 Serum

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Iodine Radioisotopes

Serum Albumin, Radio-Iodinated

Diagnostic Agents